Comment
Author: Admin | 2025-04-28
Permeability of Small Molecules for Drug Delivery Applications. Doctoral dissertation; The University of Texas at El Paso).2020. 8. Idkaidek NM, Najib N, Salem I, Jilani J. Physiologically-Based IVIVC of Azithromycin. Am J Pharmacol Sci. 2014;2(6):100–2. View Article Google Scholar 9. World Health Organization. WHO model list of essential medicines– 22nd list, 2021. 10. World Health Orgainzation: A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva(2017):1–7711. 11. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Publishing; 2021. 12. Patel J, Berezowski I, Abdelmonem A, Taylor D, Pourmand A. Azithromycin for mild- to moderate COVID-19. Lancet Respir Med.2021;9(10):99: http://dx.doi.org/10.1016/S2213-2600(21)00379-922. pmid:34509194 View Article PubMed/NCBI Google Scholar 13. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: A review. Expert Rev Anti Infect Ther. 2021;19(2):147–63: pmid:32853038 View Article PubMed/NCBI Google Scholar 14. Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More Than Just an Antimicrobial? Clin Drug Investig. 2020;40(8):683–6. pmid:32533455 View Article PubMed/NCBI Google Scholar 15. Blockman Marc, Cohen Karen, De Waal Renee, Gray A, Kredo Tamara, Maartens Gary, et al. Azithromycin for Covid‐19: Evidence Review of the clinical benefit and harm. 2020;(October):1–15. View Article Google Scholar 16. Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J. Azithromycin consumption during the COVID- 19 pandemic in Croatia, 2020. PloS One. 2022;17(2 February):2–9. View Article Google Scholar 17. Petersen A, Held N,
Add Comment